| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/01/2009 | EP2075582A2 Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers |
| 07/01/2009 | EP2075346A2 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 07/01/2009 | EP2075335A2 Methods and compositions for inhibiting neoplastic cell growth |
| 07/01/2009 | EP2075334A1 EG-VEGF nucleic acids and polypeptides and methods of use |
| 07/01/2009 | EP2075258A1 Antibody against rgd in amino acid sequence of extracellular matrix protein and production method and use of the same |
| 07/01/2009 | EP2075255A1 Human FGF-23 gene and gene expression products |
| 07/01/2009 | EP2075010A1 Pharmaceutical composition comprising cyclodextrin paclitaxel inclusion and preparation method thereof |
| 07/01/2009 | EP2075008A2 Sensitizing cells for apoptosis by selectively blocking cytokines |
| 07/01/2009 | EP2074999A1 Use of rubescensine a and derivatives thereof in pharmacy |
| 07/01/2009 | EP2074997A1 Use of Asimadoline for the treatment of digestive disorders |
| 07/01/2009 | EP2074995A1 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| 07/01/2009 | EP2074148A1 Novel antiproliferation antibodies |
| 07/01/2009 | EP2074142A1 Compounds for stimulating p-glycoprotein function and uses thereof |
| 07/01/2009 | EP2074127A1 Pyrazolo [1, 5-a]pyrimidine derivatives and their therapeutic use |
| 07/01/2009 | EP2074125A1 Phenylacetamides useful as protein kinase inhibitors |
| 07/01/2009 | EP2074122A1 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
| 07/01/2009 | EP2074120A1 Tropane compounds |
| 07/01/2009 | EP2074118A2 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| 07/01/2009 | EP2074114A1 Pyrimidinones as casein kinase ii (ck2) modulators |
| 07/01/2009 | EP2074105A1 Cyclopropyl-piperazine compounds as calcium channel blockers |
| 07/01/2009 | EP2074103A1 6-phenylpyrimidinones as pim modulators |
| 07/01/2009 | EP2073899A1 The use of a dna damaging agent and a ligand for the treatment of cancer |
| 07/01/2009 | EP2073851A1 Cytotoxicity mediation of cells evidencing surface expression of cd63 |
| 07/01/2009 | EP2073843A2 Methods of diagnosing, treating, or preventing plasma cell disorders |
| 07/01/2009 | EP2073837A2 Recombinant modified vaccinia ankara encoding a her-2 antigen for use in treating cancer |
| 07/01/2009 | EP2073835A1 Antimetastatic effect on human cell disorders |
| 07/01/2009 | EP2073830A1 Interferon type i supporting compounds |
| 07/01/2009 | EP2073826A2 Sequential combination therapy |
| 07/01/2009 | EP2073810A2 Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile compound for treating diabetes, cancer, autoimmune disorders and hiv infection |
| 07/01/2009 | EP2073809A2 Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| 07/01/2009 | EP2073806A2 Use of spiro-oxindole compounds as therapeutic agents |
| 07/01/2009 | EP2037941A4 Cobalamin compositions and methods for treating or preventing mucositis |
| 07/01/2009 | EP1861365B1 N-sulphonylpyrroles and their use as histone deacetylase inhibitors |
| 07/01/2009 | EP1809315B1 Inhibition of tumor growth and metastasis by atf2-derived peptides |
| 07/01/2009 | EP1740576B1 Novel piperidine substituted diaminothiazoles |
| 07/01/2009 | EP1686999B1 Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| 07/01/2009 | EP1684770B1 Oligo-beta-(1,3)-glucan and monoclonal antibodies against cancer |
| 07/01/2009 | EP1682126B1 Substituted benzazoles and use thereof as inhibitors of raf kinase |
| 07/01/2009 | EP1644350B1 Sulfamate benzothiophene derivatives as steroid sulfatase inhibitors |
| 07/01/2009 | EP1576159B1 The gene cluster involved in safracin biosynthesis and its uses for genetic engineering |
| 07/01/2009 | EP1565208B1 The use of cytochrome p450 enzyme cyp2wi as a drug traget for cancer therapy |
| 07/01/2009 | EP1552018B1 Methods and compositions relating to gene silencing |
| 07/01/2009 | EP1537075B1 Diarylurea derivatives and their use as chloride channel blockers |
| 07/01/2009 | EP1511721B1 Guanidino phenylalanin compounds used as urokinase inhibitors |
| 07/01/2009 | EP1471054B1 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these |
| 07/01/2009 | EP1351967B1 Compositions and methods for the therapy and diagnosis of lung cancer |
| 07/01/2009 | EP1261704B1 Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| 07/01/2009 | EP1203025B1 Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and beta1 integrins |
| 07/01/2009 | EP1124846B1 Nucleotide and protein sequences of nogo genes and methods based thereon |
| 07/01/2009 | EP1019068B1 Therapeutic formulations containing snake and/or insect venom for the prophylaxis and therapy of neoplasms |
| 07/01/2009 | EP0871748B1 Delivery of biologically active polypeptides |
| 07/01/2009 | CN101468984A N-oxyde of n-phenyl-2-pyrimidine-amine derivatives |
| 07/01/2009 | CN100506846C Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer |
| 07/01/2009 | CN100506845C IFNAR2 mutants, their production and use |
| 07/01/2009 | CN100506815C Piperidinyl targeting compounds that selectively bind integrins |
| 07/01/2009 | CN100506803C Polymorph of {6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3e) |
| 07/01/2009 | CN100506801C Inhibitors of glycogen synthase kinase 3 |
| 07/01/2009 | CN100506791C Pentafluorosulfanylbenzoylguanidines, preparation method, their use as medicaments or diagnostic aids, and medicaments comprising them |
| 07/01/2009 | CN100506788C Arylalkylcarbamate derivatives production and use thereof in therapy |
| 07/01/2009 | CN100506287C Method for preparing radioactive arsenic compound and usage for curing tumor |
| 07/01/2009 | CN100506284C Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| 07/01/2009 | CN100506277C Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| 07/01/2009 | CN100506224C Combinations comprising a selective cyclooxygenase-2 inhibitor |
| 07/01/2009 | CN100506221C Therapeutic agent for cancer |
| 06/30/2009 | USRE40811 Administering anti-VLA-4 antibody (or anti-VCAM-1 antibody) which blocks binding VLA-4 antigen on surface of CD34 cells to VCAM-1 or fibronectin, thereby increasing number of CD34+ cells in peripheral blood; colony stimulating factors |
| 06/30/2009 | US7553975 2-(((2-amino-1-oxo-3-mercapto-propyl)-amino)-methyl)-5-phenyl-thiazole-4-carbonyl-methionine; useful for treating restenosis or tissue proliferative diseases |
| 06/30/2009 | US7553966 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 06/30/2009 | US7553939 Genes that encode cell surface molecules with conserved IgV and mucin domains; diagnosis or staging of cancer; treatment of an immunological disorder; detecting a predisposition to asthma |
| 06/30/2009 | US7553918 pH-sensitive polymer |
| 06/30/2009 | US7553877 Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma |
| 06/30/2009 | US7553867 Furan or thiophene derivative and medicinal use thereof |
| 06/30/2009 | US7553859 Macrocycles for the treatment of cancer |
| 06/30/2009 | US7553852 Caspase inhibitors and uses thereof |
| 06/30/2009 | US7553845 1-Methoxy-3-(3-methoxy-4-nitrobenzoyl)-2-methylindolizin-6-yl]carboxamide; angiogenesis inhibitors; antitumor, -carcinogenic, and metastasis agent; rheumatic diseases; antiarthritic agents; atherosclerosis; retenosis; leukemia; cardiotonic agents; imflammatory bowel disease; obesity; antidiabetic agents |
| 06/30/2009 | US7553843 Process for the preparation of purified crystalline CCI-779 |
| 06/30/2009 | US7553839 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| 06/30/2009 | US7553826 Cytarabine monophosphate prodrugs |
| 06/30/2009 | US7553821 Methods for selectively modulating survivin apoptosis pathways |
| 06/30/2009 | US7553820 Mevalonic acid derivatives |
| 06/30/2009 | US7553815 Therapeutic use |
| 06/30/2009 | US7553642 Capable of sodium-independently transporting branched amino acids |
| 06/30/2009 | US7553500 6-phenyl-5-(4-(2-pyrrolidin-1-ylethoxy)phenyl)-5,6,7,8 -tetrahydronaphthalen-2-ol (laxofoxifene); a prodrug with a glidant, disintegrant, lubricant and diluent/filler in given amounts; unit dosage forms, including low dosage forms; selective estrogen receptor modulators |
| 06/30/2009 | US7553492 Gene overexpression/underexpression; antibodies; drug screening; kits |
| 06/30/2009 | US7553488 Chemokine inhibitors; for treatment of gout; for inhibiting migration of neutrophils involved in pathogenesis |
| 06/30/2009 | US7553483 Chemokine mutants acting as chemokine antagonists |
| 06/30/2009 | US7553479 Heat stable colloidal iron oxides coated with reduced carbohydrates and uses thereof |
| 06/30/2009 | CA2368812C Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy |
| 06/30/2009 | CA2330447C N-(3-ethynylphenyl-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| 06/30/2009 | CA2203480C Interferon conjugates |
| 06/30/2009 | CA2161445C Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines |
| 06/30/2009 | CA2133106C Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon |
| 06/25/2009 | WO2009079585A2 Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins |
| 06/25/2009 | WO2009079391A1 Benzofuran anilide histone deacetylase inhibitors |
| 06/25/2009 | WO2009079335A1 Binding molecules to the human ox40 receptor |
| 06/25/2009 | WO2009078992A1 Linear tricyclic compounds as p38 kinase inhibitors |
| 06/25/2009 | WO2009078804A1 Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| 06/25/2009 | WO2009078803A1 Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
| 06/25/2009 | WO2009078802A1 Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
| 06/25/2009 | WO2009078798A1 Pharmaceutically acceptable salts of methyl (3-{ [[3-(6- amino- 2-butoxy-8-oxo-7, 8-dihydro-9h-purin-9-yl) propyl] (3- morpholin-4-ylpropyl) amino] methyl }phenyl) acetate and their use in therapy |
| 06/25/2009 | WO2009078794A1 Compounds for use in the treatment of cancer |